Searchable abstracts of presentations at key conferences in obesity

ob0002p1 | (1) | OU2020

A patient with hypothalamic obesity who responded well to GLP-1 agonist therapy and thereafter mini-gastric bypass surgery

Moolla Ahmad , Miras Alexander

We present the case of a 28-year-old woman who initially presented aged 11 with a brain tumour in 2002. This was diagnosed as a craniopharyngioma and managed with neurosurgery, a ventriculoperitoneal (VP) shunt and radiotherapy. The consequence of this treatment gradually rendered her panhypopituitary and caused hypothalamic injury. Medications which were commenced around this time include hydrocortisone, thyroxine, desmopressin and growth hormone. The hypothalamic insult in t...

ob0003p2 | All items | OU2021

Resistant Hypocalcemia in a patient after Roux-en-Y gastric bypass

Boharoon Hessa , Miras Alexander

Introduction: It is known that bariatric operations cause nutritional deficiencies especially calcium and vitamin D. Reported hypocalcemia after bariatric surgery ranges from 1% after Roux-en-Y gastric bypass (RYGB) to 25% after bilio-pancreatic diversion-duodenal switch. This is mainly the result of bypassing the preferential sites for calcium and vitamin D absorption. Apart from the bariatric operations, hypocalcemia commonly...

ob0002cd1.4 | Case Discussions: Complex Clinical Cases 1 | OU2020

Liraglutide downregulates the expression of miRNA-424 in patients with obesity

Dimitriadis Georgios K , Dimitri Federica , Bate Danielle , Leca Bianca , Davasgaium Allan , Tripathi Gyanendra , Miras Alexander D , Rubino Francesco , Christian Mark , Randeva Harpal S

Aims: Liraglutide 3 mg once daily is an approved, prescription injectable Glucagon Like Peptide-1 receptor agonist that, when used with a low-calorie diet and increased physical activity, can reduce excess weight in patients with obesity. MiRNAs are small non-coding single stranded RNAs that regulate gene expression post-transcriptionally by inhibiting their mRNA target translation into proteins. MiRNAs can be secreted in the blood stream and affect the molecular pathways of d...

ob0003cd1.2 | Case Discussions 1 | OU2021

Liraglutide 3.0 mg within a NHS Tier-3/4 weight management service results in similar weight loss compared to regulatory trials – The LIPOSAX first UK real-world evidence study

Dimitriadis Georgios K , Spencer Lewis , Dimitri Federica , Bate Danielle , Leca Bianca M , Duggirala Aparna , Davasgaium Allan , Aylwin Simon JB , Miras Alexander D , Vincent Royce P , le Roux Carel W , Christian Mark , Randeva Harpal S , Tripathi Gyanendra

Liraglutide 3 mg daily is an approved, prescription injectable GLP-1 receptor agonist, which can reduce weight in patients with obesity, with or without obesity complications. We conducted a 24-week, open-label real-world study involving 62 participants with a BMI >30 kg/m2 or >27 kg/m2 if they had co-existing dyslipidaemia or hypertension. No patients had type 2 diabetes. Patients received once-daily subcutaneous liraglutide 3.0 mg, alongside NHS...